Shots:
- Cyprumed & Merck have entered into a non-exclusive license & option agreement to develop oral formulations of Merck’s peptides, leveraging Cyprumed’s innovative drug delivery tech
- As per the deal, Merck has secured non-exclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets, with an option to exclusively license it for individual targets & will be responsible for research, development, manufacturing, & commercialization efforts
- Cyprumed will receive ~$493M in upfront, development, regulatory, & sales milestones contingent on product approvals, & is eligible to receive additional payments if Merck exercises its exclusive license option
Ref: Globenewswire | Image: Cyprumed & Merck
Related News:- Merck Presents P-III (3475A-D77) Trial Data of SC Keytruda for NSCLC at ELCC 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
